4.8 Article

Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma

期刊

ONCOGENE
卷 35, 期 26, 页码 3432-3442

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.403

关键词

-

资金

  1. Associazione Italiana Ricerca sul Cancro (AIRC) [AIRC 14199, AIRC 12852]
  2. Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship

向作者/读者索取更多资源

The endothelin-1 (ET-1)/ET A receptor (ETAR) signalling pathway is a well-established driver of epithelial ovarian cancer (EOC) progression. One key process promoted by ET-1 is tumor cell invasion, which requires the scaffolding functions of beta-arrestin-1 (beta-arr1) downstream of the receptor; however, the potential role of ET-1 in inducing invadopodia, which are crucial for cellular invasion and tumor metastasis, is completely unknown. We describe here that ET-1/ETAR, through beta-arr1, activates RhoA and RhoC GTPase and downstream ROCK (Rho-associated coiled coil-forming kinase) kinase activity, promoting actin-based dynamic remodelling and enhanced cell invasion. This is accomplished by the direct interaction of beta-arr1 with PDZ-RhoGEF (postsynaptic density protein 95/disc-large/zonula occludens-RhoGEF). Interestingly, ETAR-mediated invasive properties are related to the regulation of invadopodia, as evaluated by colocalization of actin with cortactin, as well as with TKS5 and MT1-MMP (membrane type 1-matrix metalloproteinase) with areas of matrix degradation, and activation of cofilin pathway, which is crucial for regulating invadopodia activity. Depletion of PDZ-RhoGEF, or beta-arr1, or RhoC, as well as the treatment with the dual ET-1 receptor antagonist macitentan, significantly impairs invadopodia function, MMP activity and invasion, demonstrating that beta-arr1/PDZ-RhoGEF interaction mediates ETAR-driven ROCK-LIMK-cofilin pathway through the control of RhoC activity. In vivo, macitentan is able to inhibit metastatic dissemination and cofilin phosphorylation. Collectively, our data unveil a noncanonical activation of the RhoC/ROCK pathway through the beta-arr1/PDZ-RhoGEF complex as a regulator of ETAR-induced motility and metastasis, establishing ET-1 axis as a novel regulator of invadopodia protrusions through the RhoC/ROCK/LIMK/cofilin pathway during the initial steps of EOC invasion.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

YAP and endothelin-1 signaling: an emerging alliance in cancer

Piera Tocci, Giovanni Blandino, Anna Bagnato

Summary: Recent studies have shown the interaction between ET-1 and the Hippo pathway, and the ET-1R/beta-arr1 axis triggers a transcriptional interplay involving YAP and mutant p53 proteins, which function in the oncogenic signaling network. Dual ET-1 receptor antagonists can interfere with the ET-1R/YAP/mutp53 signaling interplay, hindering metastasis and therapy resistance in tumors.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Article Oncology

Functional interaction between endothelin-1 and ZEB1/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer

Rosanna Sestito, Piera Tocci, Celia Roman, Valeriana Di Castro, Anna Bagnato

Summary: This study reveals the role of endothelin-1/endothelin A receptor signaling in promoting metastasis in high-grade serous ovarian carcinoma cells by inducing the interaction between ZEB1 and YAP. It also demonstrates the involvement of Integrin-linked kinase signaling in activating the YAP/ZEB1 circuit, leading to cellular plasticity and invasion. Inhibition of this pathway with an ET-1R antagonist shows potential therapeutic effects in suppressing metastasis in vivo.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Article Oncology

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Rossella Loria, Valentina Laquintana, Stefano Scalera, Rocco Fraioli, Valentina Caprara, Italia Falcone, Chiara Bazzichetto, Marta Di Martile, Laura Rosano, Donatella Del Bufalo, Gianluca Bossi, Isabella Sperduti, Irene Terrenato, Paolo Visca, Silvia Soddu, Michele Milella, Gennaro Ciliberto, Rita Falcioni, Virginia Ferraresi, Giulia Bon

Summary: This study reveals that high expression of SEMA6A is associated with poor prognosis in BRAF-mutant melanoma and plays a critical role in promoting tumor aggressiveness and resistance to targeted therapies. SEMA6A may serve as a potential predictor for the efficacy of dual BRAF/MEK inhibition.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Article Nanoscience & Nanotechnology

Hyaluronic Acid-Polyethyleneimine Nanogels for Controlled Drug Delivery in Cancer Treatment

Emanuele Limiti, Pamela Mozetic, Sara M. Giannitelli, Filippo Pinelli, Xiaoyu Han, Danila Del Rio, Franca Abbruzzese, Francesco Basoli, Laura Rosano, Stefano Scialla, Marcella Trombetta, Giuseppe Gigli, Zhenyu J. Zhang, Emanuele Mauri, Alberto Rainer

Summary: The emulsion/evaporation method is a pivotal approach for synthesizing nanogels for controlled drug delivery. However, it is limited in its use of polymers with phase-selective solubility in organic or aqueous solutions. This study presents an innovative emulsion-based strategy for producing nanogels from water-immiscible polymers hyaluronic acid (HA) and polyethyleneimine (PEI), which are chemically crosslinked. The nanogels obtained through this surfactant-free mixed emulsion exhibit low polydispersity, good colloidal stability, and high batch-to-batch reproducibility.

ACS APPLIED NANO MATERIALS (2022)

Article Biochemistry & Molecular Biology

Peptide-Mediated Targeted Delivery of Aloe-Emodin as Anticancer Drug

Annarita Stringaro, Stefano Serra, Alessandro Gori, Annarica Calcabrini, Marisa Colone, Maria Luisa Dupuis, Francesca Spadaro, Serena Cecchetti, Alberto Vitali

Summary: This study analyzed the cell specificity, cell viability effects, intracellular distribution, and immune cell response of a new peptide conjugate of Aloe-emodin in SKBR3 and A549 cell lines. The results showed that the conjugate was more effective at reducing cell viability than AE in both cell lines, with a nuclear localization in SKBR3 cells and cytoplasmic distribution in A459 cells.

MOLECULES (2022)

Article Cell Biology

Inhibition of cholesterol transport impairs Cav-1 trafficking and small extracellular vesicles secretion, promoting amphisome formation in melanoma cells

Daniela Peruzzu, Zaira Boussadia, Federica Fratini, Francesca Spadaro, Lucia Bertuccini, Massimo Sanchez, Maria Carollo, Paola Matarrese, Mario Falchi, Francesca Iosi, Carla Raggi, Isabella Parolini, Alessandra Care, Massimo Sargiacomo, Maria Cristina Gagliardi, Katia Fecchi

Summary: In this study, the role of cholesterol transport in the endosomal degradative-secretory system was explored using the U18666A inhibitor in a metastatic human melanoma cell line (WM266-4). The results showed that U18666A induced a shift of Cav-1 from the plasma membrane to the endolysosomal compartment, affecting the formation and release of small extracellular vesicles (sEVs). The inhibitor also altered the protein composition of sEVs and reduced their transfer capacity on target cells.

TRAFFIC (2023)

Article Cell Biology

The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer

Ilenia Masi, Flavia Ottavi, Danila Del Rio, Valentina Caprara, Cristina Vastarelli, Sara Maria Giannitelli, Giulia Fianco, Pamela Mozetic, Marianna Buttarelli, Gabriella Ferrandina, Giovanni Scambia, Daniela Gallo, Alberto Rainer, Anna Bagnato, Francesca Spadaro, Laura Rosano

Summary: Dissemination of high-grade serous ovarian cancer (HG-SOC) in the omentum and intercalation into a mesothelial cell (MC) monolayer depends on functional alpha 5 beta 1 integrin (Int alpha 5 beta 1) activity. This study reveals a novel interactive signaling involving beta-arrestin1 (beta-arr1), the activation of the endothelin A receptor (ETAR) by endothelin-1 (ET-1), and the activation of Int alpha 5 beta 1, which promotes tumor cells towards invasive disease. The findings suggest that ETAR/beta-arr1 may regulate the functional pathway of Int alpha 5 beta 1 and could be considered in integrin-targeting programs.

CELL DEATH & DISEASE (2023)

Article Cell Biology

Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition

Piera Tocci, Celia Roman, Rosanna Sestito, Valeriana Di Castro, Andrea Sacconi, Ivan Molineris, Francesca Paolini, Mariantonia Carosi, Giovanni Tonon, Giovanni Blandino, Anna Bagnato

Summary: PARP inhibitors have changed the treatment paradigm of HG-SOC, but their efficacy is limited in patients with high TP53 mutation rates. The overexpression of the ET-1/ET1R axis in HG-SOC is associated with poor prognosis and inhibits the DNA damage response induced by PARP inhibitors. The ET-1R antagonist macitentan, in combination with olaparib, shows promising results in suppressing metastatic progression in HG-SOC patient-derived xenografts.

CELL DEATH & DISEASE (2023)

Article Biochemistry & Molecular Biology

Clinical profiling of MRD48 and functional characterization of two novel pathogenic RAC1 variants

Manuela Priolo, Erika Zara, Francesca Clementina Radio, Andrea Ciolfi, Francesca Spadaro, Emanuele Bellacchio, Cecilia Mancini, Francesca Pantaleoni, Viviana Cordeddu, Luigi Chiriatti, Marcello Niceta, Emilio Africa, Corrado Mammi, Daniela Melis, Simona Coppola, Marco Tartaglia

Summary: RAC1 is a member of the RAS superfamily and plays a critical role in various cellular processes. Mutations in RAC1 are associated with a rare neurodevelopmental disorder called MRD48. Our study identified two individuals with previously unreported RAC1 mutations and demonstrated their pathogenicity, showing a gain-of-function effect. We also reviewed the clinical features of MRD48 and compared it with another neurodevelopmental disorder caused by mutations in the related gene RAC3.

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

Article Oncology

The new world of RNA diagnostics and therapeutics

Giovanni Blandino, Roberto Dinami, Marco Marcia, Eleni Anastasiadou, Brid M. Ryan, Alina Catalina Palcau, Luigi Fattore, Giulia Regazzo, Rosanna Sestito, Rossella Loria, Ana Belen Diaz Mendez, Maria Chiara Cappelletto, Claudio Pulito, Laura Monteonofrio, George A. Calin, Gabriella Sozzi, Jit Kong Cheong, Ranit Aharonov, Gennaro Ciliberto

Summary: The 5th Workshop IRE on Translational Oncology was held in Rome (Italy) to discuss the significant progress made in the RNA field, focusing on diagnostic biomarkers and targeted therapies. Non-coding RNAs were highlighted for their potential in cancer diagnosis and therapy. The report collected presentations from scientists discussing recent oncology research and providing examples of RNA applications as biomarkers and therapeutics.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2023)

Meeting Abstract Immunology

Triggering of the innate antiviral response upon CCL2 neutralization in primary human macrophages involves NF-κB, JAK/STAT, and gp130 signaling

I. Farina, D. A. Covino, S. Sozzi, L. Catapano, F. Spadaro, S. Cecchetti, C. Purificato, M. C. Gauzzi, L. Fantuzzi

EUROPEAN JOURNAL OF IMMUNOLOGY (2022)

Meeting Abstract Oncology

Tumor-derived endothelin-1 recruits and activates fibroblasts to support tumor aggressiveness

Danila Del Rio, Valentina Caprara, Ilenia Masi, Francesca Spadaro, Sara Giannitelli, Alberto Rainer, Anna Bagnato, Laura Rosano

CANCER RESEARCH (2022)

暂无数据